AML treatment: conventional chemotherapy and emerging novel agents

被引：27

作者：

Forsberg, Mark ^{[1
]}

Konopleva, Marina ^{[1
]}

机构：

[1] Montefiore Einstein Canc Ctr, Dept Oncol, 1300 Morris Pk Ave, Bronx, NY 10461 USA

来源：

TRENDS IN PHARMACOLOGICAL SCIENCES | 2024年 / 45卷 / 05期

关键词：

ACUTE MYELOID-LEUKEMIA; FLT3; INHIBITORS; SINGLE-ARM; HIGH-RISK; VENETOCLAX; AZACITIDINE; CYTARABINE; DAUNORUBICIN; RESISTANCE; TRANSPLANTATION;

D O I：

10.1016/j.tips.2024.03.005

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Acute myeloid leukemia (AML) is driven by complex mutations and cytogenetic abnormalities with profound tumoral heterogeneity, making it challenging to treat. Ten years ago, the 5-year survival rate of patients with AML was only 29% with conventional chemotherapy and stem cell transplantation. All attempts to improve conventional therapy over the previous 40 years had failed. Now, new genomic, immunological, and molecular insights have led to a renaissance in AML therapy. Improvements to standard chemotherapy and a wave of new targeted therapies have been developed. However, how best to incorporate these advances into frontline therapy and sequence them in relapse is not firmly established. In this review, we highlight current treatments of AML, targeted agents, and pioneering attempts to synthesize these developments into a rational standard of care (SoC).

引用

页码：430 / 448

页数：19

共 105 条

[31] Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML [J].

DiNardo, C. D. ;

Stein, E. M. ;

de Botton, S. ;

Roboz, G. J. ;

Altman, J. K. ;

Mims, A. S. ;

Swords, R. ;

Collins, R. H. ;

Mannis, G. N. ;

Pollyea, D. A. ;

Donnellan, W. ;

Fathi, A. T. ;

Pigneux, A. ;

Erba, H. P. ;

Prince, G. T. ;

Stein, A. S. ;

Uy, G. L. ;

Foran, J. M. ;

Traer, E. ;

Stuart, R. K. ;

Arellano, M. L. ;

Slack, J. L. ;

Sekeres, M. A. ;

Willekens, C. ;

Choe, S. ;

Wang, H. ;

Zhang, V. ;

Yen, K. E. ;

Kapsalis, S. M. ;

Yang, H. ;

Dai, D. ;

Fan, B. ;

Goldwasser, M. ;

Liu, H. ;

Agresta, S. ;

Wu, B. ;

Attar, E. C. ;

Tallman, M. S. ;

Stone, R. M. ;

Kantarjian, H. M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (25) :2386-2398

[32] Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia [J].

DiNardo, Courtney D. ;

Lachowiez, Curtis A. ;

Takahashi, Koichi ;

Loghavi, Sanam ;

Xiao, Lianchun ;

Kadia, Tapan ;

Daver, Naval ;

Adeoti, Maria ;

Short, Nicholas J. ;

Sasaki, Koji ;

Wang, Sa ;

Borthakur, Gautam ;

Issa, Ghayas ;

Maiti, Abhishek ;

Alvarado, Yesid ;

Pemmaraju, Naveen ;

Bravo, Guillermo Montalban ;

Masarova, Lucia ;

Yilmaz, Musa ;

Jain, Nitin ;

Andreeff, Michael ;

Jabbour, Elias ;

Garcia-Manero, Guillermo ;

Kornblau, Steven ;

Ravandi, Farhad ;

Konopleva, Marina Y. ;

Kantarjian, Hagop M. .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (25) :2768-+

[33] Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia [J].

DiNardo, Courtney D. ;

Pratz, Keith ;

Pullarkat, Vinod ;

Jonas, Brian A. ;

Arellano, Martha ;

Becker, Pamela S. ;

Frankfurt, Olga ;

Konopleva, Marina ;

Wei, Andrew H. ;

Kantarjian, Hagop M. ;

Xu, Tu ;

Hong, Wan-Jen ;

Chyla, Brenda ;

Potluri, Jalaja ;

Pollyea, Daniel A. ;

Letai, Anthony .

BLOOD, 2019, 133 (01) :7-17

[34] Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN [J].

Doehner, Hartmut ;

Wei, Andrew H. ;

Appelbaum, Frederick R. ;

Craddock, Charles ;

DiNardo, Courtney D. ;

Dombret, Herve ;

Ebert, Benjamin L. ;

Fenaux, Pierre ;

Godley, Lucy A. ;

Hasserjian, Robert P. ;

Larson, Richard A. ;

Levine, Ross L. ;

Miyazaki, Yasushi ;

Niederwieser, Dietger ;

Ossenkoppele, Gert ;

Roellig, Christoph ;

Sierra, Jorge ;

Stein, Eytan M. ;

Tallman, Martin S. ;

Tien, Hwei-Fang ;

Wang, Jianxiang ;

Wierzbowska, Agnieszka ;

Lowenberg, Bob .

BLOOD, 2022, 140 (12) :1345-1377

[35] Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial [J].

Dohner, Hartmut ;

Symeonidis, Argiris ;

Deeren, Dries ;

Demeter, Judit ;

Sanz, Miguel A. ;

Anagnostopoulos, Achilles ;

Esteve, Jordi ;

Fiedler, Walter ;

Porkka, Kimmo ;

Kim, Hee-Je ;

Lee, Je-Hwan ;

Usuki, Kensuke ;

D'Ardia, Stefano ;

Won Jung, Chul ;

Salamero, Olga ;

Horst, Heinz-August ;

Recher, Christian ;

Rousselot, Philippe ;

Sandhu, Irwindeep ;

Theunissen, Koen ;

Thol, Felicitas ;

Dohner, Konstanze ;

Teleanu, Veronica ;

DeAngelo, Daniel J. ;

Naoe, Tomoki ;

Sekeres, Mikkael A. ;

Belsack, Valerie ;

Ge, Miaomiao ;

Taube, Tillmann ;

Ottmann, Oliver G. .

HEMASPHERE, 2021, 5 (08) :E617

[36] Mechanisms Underlying Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia [J].

Eguchi, Motoki ;

Minami, Yosuke ;

Kuzume, Ayumi ;

Chi, SungGi .

BIOMEDICINES, 2020, 8 (08)

[37] Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, doubleblind, placebo-controlled, phase 3 trial [J].

Erba, Harry P. ;

Montesinos, Pau ;

Kim, Hee-Je ;

Patkowska, Elzbieta ;

Vrhovac, Radovan ;

Zak, Pavel ;

Wang, Po -Nan ;

Mitov, Tsvetomir ;

Hanyok, James ;

Kamel, Yasser Mostafa ;

Rohrbach, Jaime E. Connolly ;

Liu, Li ;

Benzohra, Aziz ;

Lesegretain, Arnaud ;

Cortes, Jorge ;

Perl, Alexander E. ;

Sekeres, Mikkael A. ;

Dombret, Herve ;

Amadori, Sergio ;

Wang, Jianxiang ;

Levis, Mark J. ;

Schlenk, Richard F. .

LANCET, 2023, 401 (10388) :1571-1583

[38] Concurrent FLT3 Inhibitor and IDH Inhibitor Therapy in Patients with Acute Myeloid Leukemia (AML) [J].

Fathi, Amir T. ;

Perl, Alexander E. ;

Levis, Mark ;

Smith, Catherine C. ;

Brunner, Andrew M. ;

Takahashi, Koichi ;

Hock, Hanno R. ;

Hobbs, Gabriela S. ;

Narayan, Rupa ;

Moran, Jenna A. ;

Bergeron, Meghan ;

Foster, Julia E. ;

Daver, Naval ;

DiNardo, Courtney D. .

BLOOD, 2020, 136

[39] Theoretical Studies Aimed at Finding FLT3 Inhibitors and a Promising Compound and Molecular Pattern with Dual Aurora B/FLT3 Activity [J].

Fernandes, Italo Antonio ;

Resende, Deborah Braga ;

Ramalho, Teodorico Castro ;

Kuca, Kamil ;

Ferreira da Cunha, Elaine Fontes .

MOLECULES, 2020, 25 (07)

[40] A randomized phase III study of standard versus high-dose cytarabine with or without vorinostat for AML [J].

Garcia-Manero, Guillermo ;

Podoltsev, Nikolai A. ;

Othus, Megan ;

Pagel, John M. ;

Radich, Jerald P. ;

Fang, Min ;

Rizzieri, David A. ;

Marcucci, Guido ;

Strickland, Stephen A. ;

Litzow, Mark R. ;

Savoie, M. Lynn ;

Medeiros, Bruno C. ;

Sekeres, Mikkael A. ;

Lin, Tara L. ;

Uy, Geoffrey L. ;

Powell, Bayard L. ;

Kolitz, Jonathan E. ;

Larson, Richard A. ;

Stone, Richard M. ;

Claxton, David ;

Essell, James ;

Luger, Selina M. ;

Mohan, Sanjay R. ;

Moseley, Anna ;

Appelbaum, Frederick R. ;

Erba, Harry P. .

LEUKEMIA, 2024, 38 (01) :58-66

← 1 2 3 4 5 6 7 8 9 10 →